A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients with Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry (DF/HCC 18-617)
This is a prospective, multi-institutional registry of patients with newly diagnosed Triple Negative Breast Cancer (Stage I-IV). Our goal is to collect clinical data, tissue samples, blood samples, stool samples, and patient-reported data over the course of a patient’s treatment and follow-up. We aim to provide clinicians and scientists a comprehensive platform of biospecimens and data to ultimately promote and facilitate innovative future research.
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Steve Lo, MD
Sponsor(s)
Dana-Farber Cancer Institute
Location
Bennett Cancer Center
Stamford, CT 06902
Main: 203-358-8879